Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 5, 2004, Pages 415-421

  Mwinyi, Jessica ^a   Johne, Andreas ^a   Bauer, Steffen ^a   Roots, Ivar ^a   Gerloff, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANIC ANION TRANSPORTER; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; HAPLOTYPE; HEALTH STATUS; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; KINETICS; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; RACE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TIME; URINARY EXCRETION; WILD TYPE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; GENOTYPE; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; ORGANIC ANION TRANSPORT POLYPEPTIDE C; PHARMACOGENETICS; PRAVASTATIN;

EID: 2042469487     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.12.016     Document Type: Article

References (20)

1. Meier P.J., Eckhardt U., Schroeder A., Hagenbuch B., Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology. 26:1997;1667-1677
2. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 120:2001;525-533
3. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.P., et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 274:1999;37161-37168
4. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 27:1999;866-871
5. Ishizuka H., Konno K., Naganuma H., Nishimura K., Kouzuki H., Suzuki H., et al. Transport of temocaprilat into rat hepatocytes role of organic anion transporting polypeptide. J Pharmacol Exp Ther. 287:1998;37-42
6. Pang K.S., Wang P.J., Chung A.Y., Wolkoff A.W. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 28:1998;1341-1346
7. Tamai I., Nezu J., Uchino H., Sai Y., Oku A., Shimane M., et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 273:2000;351-360
8. Tirona R.G., Leake B.F., Merino G., Kim R.B. Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 276:2001;35669-35675
9. Nozawa T., Nakajima M., Tamai I., Noda K., Nezu J., Sai Y., et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9) allelic frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 302:2002;804-813
10. Michalski C., Cui Y., Nies A.T., Nuessler A.K., Neuhaus P., Zanger U.M., et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem. 277:2002;43058-43063
11. Park J.W., Siekmeier R., Merz M., Krell B., Harder S., Marz W., et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 40:2002;439-450
12. Siekmeier R., Gross W., Marz W. Determination of pravastatin by high performance liquid chromatography. Int J Clin Pharmacol Ther. 38:2000;419-425
13. Lilja J.J., Kivisto K.T., Neuvonen P.J. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 66:1999;118-127
14. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 297:2001;861-867
15. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 73:2003;554-565
16. Pan H.Y., Waclawski A.P., Funke P.T., Whigan D. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother. 27:1993;1029-1033
17. Triscari J., Rossi L., Pan H.Y. Chronokinetics of pravastatin administered in the pm compared with am dosing. Am J Ther. 2:1995;265-268
18. Kim R.B. Transporters and xenobiotic disposition. Toxicology. 181-182:2002;291-297
19. Komai T., Shigehara E., Tokui T., Koga T., Ishigami M., Kuroiwa C., et al. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol. 43:1992;667-670
20. Yamazaki M., Suzuki H., Hanano M., Tokui T., Komai T., Sugiyama Y. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol. 264:1993;G36-44